Neoadjuvant Tyrosine Kinase Inhibition in Locally-advanced Non-small Cell Lung Cancer: Two Cases and a Brief Literature Review.

Abstract

BACKGROUND:

Despite their remarkable efficacy in metastatic non-small cell lung cancer (NSCLC), EGFR- and ALK-targeted therapies have not been shown to confer any survival benefit in stage III disease, even in subsets of patients with driver mutations.

CASE STUDIES:

Here, two patients with unresectable stage III NSCLC carrying mutations in the ALK (case 1) and EGFR (case 2) genes are presented. Treatment of the patient carrying an ALK mutation with an ALK inhibitor and the patient carrying an EGFR mutation with an EGFR inhibitor resulted in dramatic and durable responses.

CONCLUSION:

These cases demonstrated that ALK or EGFR mutation-positive stage III NSCLC patients can be treated with the corresponding inhibitors. They also highlight the urgent need for prospective data to assess their potential efficacy in order to improve patient outcomes.

• Authors: Anish B Parikh, Lindsay Hammons, Jorge E Gomez
• Journal: Anticancer research (Anticancer Res) Vol. 39 Issue 2 Pg. 897-902 (Feb 2019) ISSN: 1791-7530 [Electronic] Greece
• PMID: 30711973 (Publication Type: Case Reports, Journal Article, Review)
• Copyright: Copyright© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Chemical References

• Protein Kinase Inhibitors
• ErbB Receptors
• Receptor Protein-Tyrosine Kinases

Topics

• Biopsy
• Carcinoma, Non-Small-Cell Lung (drug therapy, pathology)
• Chemotherapy, Adjuvant
• ErbB Receptors (metabolism)
• Female
• Humans
• Lung Neoplasms (drug therapy, pathology)
• Middle Aged
• Mutation
• Neoadjuvant Therapy
• Neoplasm Metastasis
• Protein Kinase Inhibitors (therapeutic use)
• Receptor Protein-Tyrosine Kinases (chemistry)
• Smoking
• Treatment Outcome